Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 298

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 298
---
 and assignment. The main reason for the parties’ determination to exclude the DOXA asset from the CVR Agreement while including all of its other existing R&D assets under development was the DOXA program’s potential commercial and research and development synergies with the Kadimastem technology. The other reason was that the DOXA program has a relatively modest capital requirement as a preclinical asset. The parties determined in the negotiations that it would be inefficient to further develop all other existing R&D assets under development at NLS by the combined company. Regular meetings by phone call and video conference took place during this period, some of which included the parties’ respective legal counsel and financial advisors. The terms negotiated between the parties, among others, included the responsibilities of the rights agent, mechanics of the distribution, and term of the CVR Agreement. On September6, 2024, NLS and Kadimastem had a call to discuss the capital structure of the combined company following the Merger. On September9, 2024, NLS, Kadimastem, and Donohoe Advisors had a call to discuss Donohoe Advisors’ analysis of the financial projections of the combined company and the extraordinary general meeting of NLS shareholders invitation. On September 17, 2024, Sullivan sent the initial draft of the NLS Support Agreement to Pearl Cohen. Between September 17, 2024 and November 4, 2024, Sullivan and Pearl Cohen exchanged drafts and negotiated the terms of the NLS Voting Agreement. Regular meetings by phone call and video conference took place during this period, some of which included the parties’ respective legal counsel and financial advisors. On September18, 2024, NLS, Kadimastem, Sullivan and Pearl Cohen had a call to discuss the material terms of the Merger Agreement. On September19, 2024, NLS, Kadimastem, Sullivan and Pearl Cohen had a call to discuss the effective date of NLS’s reverse stock split and the NLS registration statement on Form F -4. On September 22, 2024, Pearl Cohen sent the initial draft of the Kadimastem Voting Agreement to Sullivan. Between September 22, 2024 and November 4, 2024, Sullivan and Pearl Cohen exchanged drafts and negotiated the terms of the Kadimastem Voting Agreement. Regular meetings by phone call and video conference took place during this period, some of which included the parties’ respective legal counsel and financial advisors. On September 23,